Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novavax Inc (NVAX)

Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,496,879
  • Shares Outstanding, K 160,094
  • Annual Sales, $ 983,710 K
  • Annual Income, $ -545,060 K
  • EBIT $ -293 M
  • EBITDA $ -252 M
  • 60-Month Beta 2.10
  • Price/Sales 1.56
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 88.82% ( -7.87%)
  • Historical Volatility 96.27%
  • IV Percentile 27%
  • IV Rank 42.81%
  • IV High 187.27% on 05/13/24
  • IV Low 15.11% on 11/28/23
  • Put/Call Vol Ratio 0.38
  • Today's Volume 11,544
  • Volume Avg (30-Day) 21,750
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 333,235
  • Open Int (30-Day) 351,939

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.87
  • Number of Estimates 4
  • High Estimate -0.46
  • Low Estimate -1.09
  • Prior Year -1.26
  • Growth Rate Est. (year over year) +30.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.90 +2.53%
on 11/04/24
13.77 -33.78%
on 10/07/24
-4.49 (-32.99%)
since 10/04/24
3-Month
8.87 +2.82%
on 08/08/24
15.22 -40.08%
on 10/02/24
-2.66 (-22.58%)
since 08/02/24
52-Week
3.53 +158.18%
on 02/05/24
23.86 -61.78%
on 06/06/24
+2.06 (+29.18%)
since 11/03/23

Most Recent Stories

More News
3 Spooky Signs That You're About to Lose Your Money on a Healthcare Stock Investment

Knowing these will help you avoid making suboptimal investing decisions.

TDOC : 8.87 (-3.69%)
NVAX : 9.12 (-2.46%)
PFE : 27.76 (-1.17%)
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?

Let's look beyond this piece of bad news from regulators.

NVAX : 9.12 (-2.46%)
SNY : 52.95 (-0.60%)
How Bad Is This News for Novavax?

Novavax stock fell 20% in one trading session on the news.

NVAX : 9.12 (-2.46%)
MRNA : 53.54 (-2.00%)
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.Here's...

JAZZ : 109.41 (-0.94%)
EXEL : 34.29 (+0.50%)
NVAX : 9.12 (-2.46%)
VNDA : 4.85 (+4.08%)
Should You Buy Novavax Stock After This Regulatory Win?

The biotech continues to earn important wins, but is it enough?

MRNA : 53.54 (-2.00%)
BNTX : 108.97 (-2.25%)
JNJ : 158.24 (-1.18%)
PFE : 27.76 (-1.17%)
NVAX : 9.12 (-2.46%)
SNY : 52.95 (-0.60%)
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?

Regulators recently approved an updated COVID shot from Novavax.

NVAX : 9.12 (-2.46%)
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END

SBFM : 2.89 (+1.76%)
NVAX : 9.12 (-2.46%)
RGNX : 8.76 (-0.34%)
BNTX : 108.97 (-2.25%)
ABBV : 200.47 (-1.51%)
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

SBFM : 2.89 (+1.76%)
NVAX : 9.12 (-2.46%)
RGNX : 8.76 (-0.34%)
BNTX : 108.97 (-2.25%)
ABBV : 200.47 (-1.51%)
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?

Don't be too quick to jump on the Wall Street bandwagon.

SNY : 52.95 (-0.60%)
PFE : 27.76 (-1.17%)
NVAX : 9.12 (-2.46%)
Novavax: Q2 Earnings Snapshot

Novavax: Q2 Earnings Snapshot

NVAX : 9.12 (-2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple...

See More

Key Turning Points

3rd Resistance Point 9.72
2nd Resistance Point 9.51
1st Resistance Point 9.31
Last Price 9.12
1st Support Level 8.91
2nd Support Level 8.70
3rd Support Level 8.51

See More

52-Week High 23.86
Fibonacci 61.8% 16.09
Fibonacci 50% 13.70
Fibonacci 38.2% 11.30
Last Price 9.12
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar